Clinical Trials Sponsored by RAPT Therapeutics, Inc.

Total 2975 results

Jeff C. Huffman, MD
BioXcel Therapeutics Inc

Withdrawn

Dexmedetomidine Sublingual Film for the Management of Agitation in Delirium: Safety and Preliminary Efficacy

Delirium
Allarity Therapeutics
Smerud Medical Research International AS; Lantern Pharma Inc.

Active, not recruiting

Irofulven in AR-targeted and Docetaxel-Pretreated mCRPC Patients With Drug Response Predictor (DRP®)

Metastatic Castration-Resistant Prostate Cancer Patients

Denmark
Y-mAbs Therapeutics
Invicro; Labcorp Corporation of America Holdings, Inc

Withdrawn

131I-omburtamab Delivered by Convection-Enhanced Delivery in Patients With Diffuse Intrinsic Pontine Glioma

DIPG
Merit E. Cudkowicz, MD
Denali Therapeutics Inc.

Enrolling by invitation

HEALEY ALS Platform Trial - Regimen G DNL343

Amyotrophic Lateral Sclerosis

United States
Guru P. Sonpavde
QED Therapeutics, Inc.

Withdrawn

Phase I BLASST-3 Trial ((BLASST)-3)

Bladder Cancer | Bladder Transitional Cell Carcinoma | Fibroblast Growth Factor Receptor
Tulane University School of Medicine
Karyopharm Therapeutics Inc

Withdrawn

Elotuzumab, Selinexor, and Dexamethasone for Relapsed Refractory Multiple Myeloma (ESdRRMM)

Refractory Multiple Myeloma | Relapsed Multiple Myeloma
Aevi Genomic Medicine, LLC, a Cerecor company

Completed

Efficacy and Safety of NFC-1 in Adolescents With Genetic Disorders Impacting mGluR and ADHD

Attention Deficit Disorder With Hyperactivity

United States
Aevi Genomic Medicine, LLC, a Cerecor company

Completed

PART B: Efficacy and Safety of AEVI-001 in Children and Adolescents With ADHD and Without mGluR Mutations

Attention Deficit Hyperactivity Disorder

United States
Pain Therapeutics
National Institute on Aging (NIA)

Completed

PTI-125 for Mild-to-moderate Alzheimer's Disease Patients

Alzheimer Disease

United States
Aevi Genomic Medicine, LLC, a Cerecor company

Completed

A Non-interventional Study to Identify Children and Adolescents With ADHD and With or Without mGLuR Mutations

Attention Deficit Hyperactivity Disorder

United States
Ception Therapeutics
Cephalon

Completed

Open-Label Extension Study of Reslizumab in Pediatric Subjects With Eosinophilic Esophagitis

Eosinophilic Esophagitis

United States, Canada
University of Michigan Rogel Cancer Center
Celgene; Onyx Therapeutics, Inc.

Completed

Carfilzomib and Lenalidomide With Dexamethasone Combination in Newly Diagnosed, Previously Untreated Multiple Myeloma

Multiple Myeloma

United States
Motus Therapeutics, Inc.
Michael J. Fox Foundation for Parkinson's Research

Terminated

A Phase 2 Study to Evaluate the Safety and Efficacy of RM-131 in Patients With Parkinson's Disease & Chronic Constipation (MOVE-PD)

Parkinson's Disease

United States
Ception Therapeutics
Cephalon

Completed

Efficacy and Safety Study of Reslizumab to Treat Poorly Controlled Asthma

Asthma

United States, Canada
Iworks Laser and Vision Center
Ocular Therapeutix, Inc.

Completed

Efficacy of Dextenza Insert in Upper vs Lower Punctum Following Cataract Surgery With PCIOL. (DEXTENZA)

Cataract

United States
Retina Vitreous Associates of Florida
Ocular Therapeutix, Inc.

Terminated

Effect on Pain and Inflammation With DEXTENZA Treatment in Patients Undergoing Intravitreal Anti-VEGF Injections (DETeR)

Diabetic Macular Edema | Retinal Vein Occlusion | Neovascular Age-related Macular Degeneration

United States
Massachusetts Eye and Ear Infirmary
Ocular Therapeutix, Inc.

Withdrawn

Evaluation of Dextenza in Patients With Ocular GVHD and Effects on Ocular Surface Disease Outcomes

Graft Vs Host Disease

United States
Ophthalmic Consultants of Long Island
Ocular Therapeutix, Inc.

Unknown

A Trial Evaluating Patient Preference of Dropless vs Drops Post Cataract Surgery (CIMPLIFY)

Patient Preference

United States
Juno Therapeutics, Inc., a Bristol-Myers Squibb...
Celgene Corporation

Not yet recruiting

A Study to Evaluate the Efficacy and Safety of Liso-cel Compared to Standard of Care in Adults With Relapsed or Refractory Follicular Lymphoma

Relapsed or Refractory Follicular Lymphoma
Juno Therapeutics, Inc., a Bristol-Myers Squibb...
Celgene Corporation

Recruiting

A Study to Evaluate the Safety, Tolerability, Efficacy, and Drug Levels of CC-97540 in Participants With Relapsing Forms of Multiple Sclerosis or Progressive Forms of Multiple Sclerosis

Multiple Sclerosis

United States, Belgium, France, Germany, Spain, United Kingdom, Italy
Seventh Medical Center of PLA General Hospital
GeneCradle Therapeutics, Inc

Recruiting

Clinical Exploration of Adeno-associated Virus (AAV) Expressing Human Acid Alpha- Glucosidase (GAA) Gene Therapy for Patients With Infantile-onset Pompe Disease

Infantile-onset Pompe Disease

China
Edwin Posadas, MD
Enviro Therapeutics, Inc.

Recruiting

Study of Apalutamide With Carotuximab in Metastatic, Castration-Resistant Prostate Cancer

Castration-resistant Prostate Cancer

United States
Anup Kasi
Cend Therapeutics Inc.

Recruiting

CEND-1 in Combination With Neoadjuvant FOLFIRINOX With or Without Panitumumab (CENDIFOX)

Colon Cancer | Pancreas Cancer | Digestive Cancer

United States
Jonsson Comprehensive Cancer Center
Mirati Therapeutics Inc.; Phase One Foundation

Recruiting

Mocetinostat With Vinorelbine in Children, Adolescents & Young Adults With Refractory and/or Recurrent Rhabdomyosarcoma

Rhabdomyosarcoma

United States
Sanjay Mohan
AbbVie; Karyopharm Therapeutics Inc

Active, not recruiting

Venetoclax and Selinexor in Treating Patients With Relapsed or Refractory High Risk Hematologic Malignancies

Acute Myeloid Leukemia | Non-Hodgkin's Lymphoma | Diffuse Large B-cell Lymphoma

United States
Juno Therapeutics, Inc., a Bristol-Myers Squibb...
Celgene Corporation

Withdrawn

A Study to Compare the Efficacy and Safety of Lisocabtagene Maraleucel vs Investigator's Choice Options in Adult Participants With Relapsed or Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma, Whose Disease Has Failed Treatment With Both BTKi and BCL2i Therapies

Leukemia, Lymphocytic, Chronic, B-Cell

United States, Austria, Belgium, France, Germany, Italy, Netherlands, Norway, Spain, Sweden, United Kingdom
Glenn J. Hanna
Actuate Therapeutics Inc.

Active, not recruiting

9-ING-41 Plus Carboplatin in Salivary Gland Carcinoma

Adenoid Cystic Carcinoma | Metastatic Cancer | Salivary Gland Cancer | Recurrent Salivary Gland Cancer

United States
Children's Oncology Group
National Cancer Institute (NCI); SpringWorks Therapeutics, Inc.

Active, not recruiting

A Study of a New Drug, Nirogacestat, for Treating Desmoid Tumors That Cannot be Removed by Surgery

Desmoid Fibromatosis | Recurrent Desmoid Fibromatosis | Unresectable Desmoid Fibromatosis

United States, Canada, Puerto Rico, Australia, New Zealand
Merit E. Cudkowicz, MD
Seelos Therapeutics, Inc.

Completed

HEALEY ALS Platform Trial - Regimen E SLS-005 - Trehalose

Amyotrophic Lateral Sclerosis

United States
Memorial Sloan Kettering Cancer Center
Stanford University; Juno Therapeutics, Inc.

Active, not recruiting

Cyclophosphamide Followed by Intravenous and Intraperitoneal Infusion of Autologous T Cells Genetically Engineered to Secrete IL-12 and to Target the MUC16ecto Antigen in Patients With Recurrent MUC16ecto+ Solid Tumors

Solid Tumors

United States
Aevi Genomic Medicine, LLC, a Cerecor company

Completed

Safety and Efficacy Study of NFC-1 in Subjects Aged 12-17 Years With 22q11.2DS & Associated Neuropsychiatric Conditions

22q11.2 Deletion Syndrome

United States
Craig McDonald, MD
Cardero Therapeutics, Inc.

Completed

(-)- Epicatechin Becker Muscular Dystrophy

Becker Muscular Dystrophy

United States
Pain Therapeutics
National Institute on Aging (NIA)

Completed

A Safety Study of PTI-125 in Healthy Volunteers

Alzheimer Disease | Alzheimer Disease, Early Onset

United States
Acorda Therapeutics
United States Department of Defense; DP Clinical, Inc.

Terminated

AC105 in Patients With Acute Traumatic Spinal Cord Injury (AC105)

Acute Spinal Cord Injury
VA Office of Research and Development
Helsinn Therapeutics (U.S.), Inc

Terminated

The Role of Ghrelin in Cancer Cachexia

Cancer Cachexia

United States
Johns Hopkins University
Juvenile Diabetes Research Foundation; iCo Therapeutics Inc.

Terminated

A Randomized, Multi-center, Phase II Study of the Safety, Tolerability and Bioactivity of Repeated Intravitreal Injections of iCo-007 as Monotherapy or in Combination With Ranibizumab or Laser Photocoagulation in the Treatment of Diabetic Macular Edema (the iDEAL Study) (iDEAL)

Diabetic Macular Edema

United States
Radboud University Medical Center
Dutch Heart Foundation; Synvista Therapeutics, Inc

Completed

Effects of Exercise Training and AGE-crosslink Breaker on Cardiovascular Structure and Function

Cardiovascular Disease | Physical Activity | Aging | Endothelial Dysfunction

Netherlands
Mitchel Ibach
Ocular Therapeutix, Inc.

Not yet recruiting

In Clinic Optometrist Insertion of Dextenza Prior to Cataract Surgery (Prepare)

Cataract
Clinical Research Center of Florida
Ocular Therapeutix, Inc.

Completed

DEXTENZA Therapy for Treatment of Allergic Conjunctivitis

Bilateral Conjunctivitis (Disorder)

United States
Nathan Steinle
Ocular Therapeutix, Inc.

Unknown

INtravitreal and Aqueous Dexamethasone Levels After DEXtenza (INDEX)

Ocular Disease Requiring Surgery

United States
University of Cologne
Pfizer; F2G Biotech GmbH; Basilea Pharmaceutica; Cidara Therapeutics Inc.; Matinas...

Recruiting

FungiScope - A Global Emerging Fungal Infection Registry (FungiScope)

Invasive Fungal Disease

Germany
Rempex (a wholly owned subsidiary of Melinta Therapeutics...
Department of Health and Human Services

Recruiting

Dose-finding, Pharmacokinetics, and Safety of VABOMERE in Pediatric Subjects With Bacterial Infections (TANGOKIDS)

Bacterial Infections

United States
Modulation Therapeutics, Inc.
H. Lee Moffitt Cancer Center and Research Institute

Recruiting

Targeted Alpha Particle Radiotherapy for Metastatic Uveal Melanoma

Uveal Melanoma | Metastatic

United States
Karen Reckamp, MD, MS
Enviro Therapeutics, Inc.

Recruiting

Study of Osimertinib With Carotuximab in Advanced, EGFR-mutated Non-Small Cell Lung Cancer

Lung Cancer | Non Small Cell Lung Cancer

United States
IVI Vigo
Instituto Valenciano de Infertilidad, IVI VALENCIA; Juno Therapeutics, Inc.

Not yet recruiting

Embryos With Preimplantation Genetic Testing for Aneuploidies (PGT-A) Inconclusive Result: Clinical Implications

Embryo Disorder
Barbara Parker, MD
Oncternal Therapeutics, Inc

Completed

Study of Cirmtuzumab and Paclitaxel for Metastatic or Locally Advanced, Unresectable Breast Cancer

Breast Neoplasms

United States
Alice Mims
Karyopharm Therapeutics Inc

Completed

Selinexor and Chemotherapy in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia

Recurrent Adult Acute Myeloid Leukemia | Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities | Adult Acute Myeloid Leukemia With Del(5q) | Adult Acute Myeloid Leukemia With Inv(16)(p13;q22) | Adult Acute Myeloid Leukemia With t(16;16)(p13;q22) | Adult Acute Myeloid Leukemia With t(8... and other conditions

United States
Kari Kendra
Karyopharm Therapeutics Inc

Completed

Evaluating SINE KPT-330 in Treating Patients With Melanoma That Cannot Be Removed By Surgery (KPT-330)

Recurrent Melanoma

United States
Insight Therapeutics, LLC
Brown University; Genentech, Inc.; Case Western Reserve University

Active, not recruiting

Baloxavir Versus Oseltamivir for Nursing Home Influenza Outbreaks

Influenza | Influenza, Human | Influenza -Like Illness

United States
H. Lee Moffitt Cancer Center and Research Institute
Karyopharm Therapeutics Inc

Completed

Selinexor (KPT-330) and Liposomal Doxorubicin For Relapsed and Refractory Multiple Myeloma

Multiple Myeloma

United States

Clinical Trials Sponsored by RAPT Therapeutics, Inc.

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Israel

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations